ReviewMolecular and cellular biochemistry2025
The effect of TMAO on aging-associated cardiovascular and metabolic pathways and emerging therapies.
Review in Molecular and cellular biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- The TMAO Metabolic Axis in Vascular Disease: A Position Paper on Redox Mechanisms and Priorities for Clinical Translation.Antioxidants (Basel, Switzerland) · 2026Article
- Trimethylamine N-oxide in exercise physiology: a gut microbiota-derived signal linking metabolic stress, redox balance and cardiometabolic health.European journal of applied physiology · 2026Review
- Cardiometabolic Aging Driven by Multi-Organ Crosstalk: Mechanisms and Therapeutic Strategies.International journal of molecular sciences · 2026Review
- Gut Microbiome-Hormone Interactions and Precision Fermentation in the Prevention of Early Cardiovascular Risk in Adolescents.International journal of molecular sciences · 2026Review
- Intervening at the microbial crossroads: targeting inflammation across the oral-gut-reproductive microbiome crosstalk in atherosclerosis.Antonie van Leeuwenhoek · 2026Review
- Dietary Nutrients, Gut Microbiota, and Cardiac Function: From Metabolic Mechanisms to Clinical Applications.Nutrients · 2026Review
- Review
- Gut Microbiota-Derived Trimethylamine N-Oxide and NT-proBNP in Heart Failure: A Critical Review of Diagnostic and Prognostic Value.Biomedicines · 2026Review
- The gut microbiome-cardiometabolic axis: insights into obesity, type 2 diabetes, and hypertension.Frontiers in endocrinology · 2026Review
- Revisiting the Thyroid-Heart Axis: Unravelling the Interplay of Hormones, Epigenomes and Precision Cardioprotection.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metabolites produced by gut microbes have been linked to the pathophysiology of several disorders, including cardiovascular disease (CVD), such as atherosclerosis, hypertension, heart failure, and myocardial infarction. Trimethylamine-N-oxide (TMAO) is a primary diet-induced metabolite generated by the gut microbiota. TMAO is involved in dysregulation of bile acid and cholesterol metabolism, which promotes oxidative stress, inflammation, and endothelial dysfunction leading to vascular damages. Aging is usually associated with cardio-metabolic diseases, and the increasing evidence reveals that TMAO is linked with an increased risk of CVD in elderly. However, the exact relationship between plasma TMAO levels, the risk of CVD, and aging remains unclear. In this review, we explore the three-dimensional relationship between TMAO, aging, and CVD. Moreover, we discussed the new therapies used to reduce TMAO levels in aging and CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.